• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Remdesivir Being Evaluated with Other Treatments for COVID-19

Remdesivir Being Evaluated with Other Treatments for COVID-19

May 18, 2020

After Gilead Sciences’ remdesivir was approved for emergency use on COVID-19 patients, a number of other trials have gotten underway to test the antiviral’s benefits in combination with other drugs.

Researchers at the University of Southern California are conducting a trial of moderate to severe cases of COVID-19 to see if adding Eli Lilly’s Olumiant (baricitinib) to remdesivir can reduce the need for invasive mechanical ventilation, according to Informa Pharma Intelligence, a market research firm that is tracking remdesivir trials. The National Institutes of Health is currently conducting a similar trial, but it is limited to severe cases.

Another trial at the University of Kansas is testing antihypertensive drug Cozaar (losartan) as a COVID-19 treatment, and it will also evaluate any potential interactions with remdesivir.

One trial being conducted at the VA Boston Healthcare System is testing rheumatoid arthritis drug Kevzara (sarilumab) and remdesivir with standard of care for moderate COVID-19 cases.

Meanwhile, a trial in Iran is studying remdesivir on top of standard of care, which includes some variation of chloroquine phosphate/hydroxychloroquine sulfate, lopinavir/ritonavir or atazanavir.

And a trial in Croatia is evaluating Roche’s Actemra (tocilizumab) with standard of care. In this trial, remdesivir is considered a standard of care treatment.

Researchers in France are testing dexamethasone with standard oxygen to support patients with severe COVID-19. Patients that are included in the trial are also being treated with remdesivir.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing